Emerald was founded in 2010 by two scientists and life-long friends from Philadelphia with a singular vision of how a biotechnology company should run. Frustrated by the continual deceleration of innovation and the exponentially increasing R&D costs in the pharmaceutical sector, Emerald models itself after the legendary start-up companies of the mid-20th century that built the core technologies underlying the meteoric rise of the semiconductor industry. The team places as much focus on building tools around how scientific research is conducted as they do on their proprietary anti-viral therapies. In this way, Emerald is striving to bring a Moore’s law-like acceleration to life sciences innovation.
Funding Rounds (3) - $34MUpdate
|Dec 14, 2015||NYT Bits - Stephen Wolfram Aims to Democratize His Software|
|Jul 1, 2015||Inc.com - How Peter Thiel Is Trying To Save The World|
|May 16, 2015||CNet - Science labs in the cloud: Champagne discoveries, beer budget - CNET|
|Apr 21, 2015||Inc.com - A Biotech Lab in the Cloud, Backed by Peter Thiel|
|Mar 25, 2015||Business Wire - Emerald Therapeutics Unveils ECL-1: The First Emerald Cloud Lab Production Facility and Announces First Customers|
|Jul 8, 2014||TechCrunch - Experimenting With Drugs In The Cloud|
|Jul 3, 2014||Bloomberg - Emerald Therapeutics: Biotech Lab for Hire|
|Jul 2, 2014||FinSMEs - Emerald Therapeutics Completes $13.5M Financing|
844 Dubuque Ave.
South San Francisco, California 94080